The four tracks

The ISA2015 committee has designed a scientific program that will address all relevant topics and developments in atherosclerosis and cardiovascular disease in four tracks: Dyslipidaemia, Pathogenesis, Prevention and Epidemiology of Atherosclerosis. 

dyslipidemia

Track Nº1 Dyslipidemia

An insight into the latest developments concerning lipids, lipoproteins and apolipoproteins.

Learn about the latest developments surrounding genetics, Mendelian randomisation studies and animal and human biology in lipid, lipoprotein and apolipoprotein research. Results from recently completed intervention trials will also be presented.

We have created three sub-tracks in the dyslipidaemia track: Basic Science, Translational Research and Clinical studies. Create your own ‘tailor made’ programme throughout our entire event in Amsterdam.

Highlights of the dyslipidaemia track:

  • New findings on the crucial role of apolipoprotein AI in HDL function.
  • The pivotal role of apolipoprotein CIII in the pathogenesis of hypertriglyceridemia & CVD.
  • The LDL/PCSK9 axis in the development of new strategies in the fight against CVD risk.
pathogenesis

Track Nº2 The Pathogenesis of CVD

On immunity, inflammation and the endothelium

Enrich your knowledge with the most recent findings on the importance of innate and acquired immunity, low grade inflammation. Learn about their interactions with both monocytic and endothelial cells for the development of atherosclerotic vascular disease.

The Basic Science, Translational Research and Clinical studies sub-track allow you to compile a personal tailor-made programme of the pathogenesis of atherosclerosis track.

Highlights of the pathogenesis of atherosclerosis track include:

  • The significance of angiogenesis for plaque progression,
  • The epigenetic programming of the monocyte/macrophage in relation to trained immunity
  • Immunomodulation therapy with a plethora of novel interventions to lower CVD risk.
  • The latest imaging modalities to visualize atherosclerosis and the unstable plaque.
epidemiology

Track Nº3 Epidemiology of CVD

Exploring the Risk Factor Concept.

This track revisits and integrates epidemiologic data from the previous as well as the current century. It addresses association versus causality of the risk factor concept. You will explore the reconciliation of the most recent results of Mendelian randomisation studies with the outcomes of the Emerging Risk Factor Collaboration.

Highlights of the epidemiology of CVD track include:

  • Using genetics to establish the causality of a risk factor for atherosclerotic vascular disease;
  • The contribution of specific food intake to the occurrence of CVD;
  • The refinement of epidemiological tools to personalize risk stratification.
prevention

Track Nº4 Primary & Secondary prevention of CVD

Lifestyle Measures & Pharmacological Intervention

Bring your knowledge up to speed by learning about the latest findings in both effective primary and secondary prevention.

Lifestyle measures include cessation of smoking, dietary measures, weight reduction and exercise. Pharmacological interventions cover coagulation, platelet inhibition, diabetes mellitus, hypertension, weight reduction as well as dyslipidaemia. Recent insights from randomised interventional trials in the secondary prevention arena will also be covered.

A thorough discussion of the European, US and UK guideline updates as published late 2014, will help you put these intervention outcomes into perspective.

Stay up to date, subscribe to the newsletter

Progression and prevention of atherosclerosis and a translation to relevance.